Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry Heijerman

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Lancet (London, England)|August 31, 2020
Transparency and diversity in cystic fibrosis research - Authors' replyKaren S McCoy, Harry Heijerman, Jennifer L Taylor-Cousar, et al.
BMJ Open Respiratory Research|May 3, 2024
Considerations for the use of inhaled antibiotics for <i>Pseudomonas aeruginosa</i> in people with cystic fibrosis receiving CFTR modulator therapyPierre-Régis Burgel, Manfred Ballmann, Pavel Drevinek, et al.
Journal of Personalized Medicine|December 24, 2021
Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR ModulatorsDanya Muilwijk, Marlou Bierlaagh, Peter van Mourik, et al.
Plos One|June 10, 2016
The Effect of Strict Segregation on Pseudomonas aeruginosa in Cystic Fibrosis PatientsRosa van Mansfeld, Angelica de Vrankrijker, Roland Brimicombe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 16, 2022
Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftorIsabelle Fajac, Cori Daines, Isabelle Durieu, et al.
Pediatric Pulmonology|April 2, 2020
Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutationM Marcella Burghard, G Gitte Berkers, S Sophie Ghijsen, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 29, 2020
Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutationGitte Berkers, Renske van der Meer, Harry Heijerman, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2014
European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis CentreSteven Conway, Ian M Balfour-Lynn, Karleen De Rijcke, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Lancet (London, England)|August 31, 2020
Transparency and diversity in cystic fibrosis research - Authors' replyKaren S McCoy, Harry Heijerman, Jennifer L Taylor-Cousar, et al.
BMJ Open Respiratory Research|May 3, 2024
Considerations for the use of inhaled antibiotics for <i>Pseudomonas aeruginosa</i> in people with cystic fibrosis receiving CFTR modulator therapyPierre-Régis Burgel, Manfred Ballmann, Pavel Drevinek, et al.
Journal of Personalized Medicine|December 24, 2021
Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR ModulatorsDanya Muilwijk, Marlou Bierlaagh, Peter van Mourik, et al.
Plos One|June 10, 2016
The Effect of Strict Segregation on Pseudomonas aeruginosa in Cystic Fibrosis PatientsRosa van Mansfeld, Angelica de Vrankrijker, Roland Brimicombe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 16, 2022
Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftorIsabelle Fajac, Cori Daines, Isabelle Durieu, et al.
Pediatric Pulmonology|April 2, 2020
Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutationM Marcella Burghard, G Gitte Berkers, S Sophie Ghijsen, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 29, 2020
Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutationGitte Berkers, Renske van der Meer, Harry Heijerman, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2014
European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis CentreSteven Conway, Ian M Balfour-Lynn, Karleen De Rijcke, et al.
Pageof 2